United States

Trial Shows Treatment Convenience Most Important to Horse Owners

EXCEDE® (ceftiofur crystalline free acid) Sterile Solution provided increased treatment compliance and horse owner satisfaction when treating equine bacterial infections
 
By Mark Crisman, DVM, MS, Dipl. ACVIM, equine technical services veterinarian, Zoetis

Veterinarians often assume horse owners will prefer the lowest-cost treatment option if it provides equivalent efficacy to a higher-priced alternative. However, this assumption leaves out two key factors: treatment compliance and client convenience.

To provide veterinarians confidence in their treatment recommendations, Zoetis examined veterinarian as well as horse owner preference and satisfaction between two efficacious treatments for equine bacterial infections.

Horse owners were given the choice of two anti-infective (AIF) treatment regimens:

1. Intramuscular (IM) injection with EXCEDE® (ceftiofur crystalline free acid) Sterile Solution administered by the veterinarian four days apart, or
2. Client administration of oral trimethoprim-sulfonamide (TMS) tablets twice daily for 10 consecutive days.

Horses were examined on Day 4 to evaluate treatment response, administer the second IM dose to horses being treated with EXCEDE and, in the case of the TMS group, to verify compliance in administering oral AIF medication. The study examined 27 veterinarians from 11 equine practices in various regions of the U.S. In total, the treatment of 137 horses was included.1

Overwhelmingly, 93.1% of horse owners selected two doses of EXCEDE over twice-daily oral TMS treatment for 10 days.1

The average treatment response scores for both AIF regimens were comparable at Days 0 and 10. However, 100% of the horses treated with EXCEDE achieved full treatment compliance compared with 75% of horses treated with oral TMS tablets.1

Notably, there was a wide variance in the veterinarian’s pre-treatment cost estimate per horse with the estimated cost of EXCEDE more than double that of TMS (Table 1). However, the pre-treatment estimate differed markedly from the actual costs incurred. In the average actual cost, treatment with EXCEDE was just $20.80 greater than the TMS treatment.1

In a post-treatment survey, convenience was judged more important than price in the horse owner’s perception of value, with mean scores of 4.3 versus 3.5, respectively. The item with the greatest score differential was convenience, where EXCEDE had a near-perfect average score of 4.8 versus 3.0 for TMS. Overall client satisfaction when EXCEDE was selected had a mean score of 4.7, approaching the maximum possible score of 5.0 (Figure 1).1

The trial proved horse owners overwhelmingly prefer the most convenient therapeutic option despite higher cost. To learn more about the study or the benefits of EXCEDE, talk with your Zoetis representative or visit www.EXCEDE.com.

IMPORTANT SAFETY INFORMATION
People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to EXCEDE. EXCEDE is contraindicated in animals with known allergy to ceftiofur or to the β-lactam group (penicillins and cephalosporins) of antimicrobials. Do not use in horses intended for human consumption. The administration of antimicrobials in horses under conditions of stress may be associated with diarrhea, which may require appropriate veterinary therapy. See full Prescribing Information.

About Zoetis
Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetisUS.com.

For more information, contact:
Jaci Boggs, DVM, MS, Dipl. ACVIM 
Zoetis 
jacquelin.boggs@zoetis.com

Kassi Hoxmeier
Bader Rutter
khoxmeier@bader-rutter.com
262-938-5522

Reference:
1 Data on file, Study Report No. 14EQRGAIF02, Zoetis Inc.